vTv Therapeutics Announces $15 Million of Class A Common Stock Financings

Proceeds Will Fund Start-Up Activities for Current and Future
Clinical Trials

HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that
it has entered into a definitive agreement with certain institutional
investors for the purchase and sale in a registered direct offering (the
“Registered Direct Offering”) of 3,636,364 shares of the Company’s Class
A common stock (the “Common Stock”) at a price of $1.65 per share for
aggregate gross proceeds of approximately $6.0 million. The offering is
expected to close on or about March 20, 2019, subject to the
satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent.

The Company also entered into a letter agreement (the “Letter
Agreement”) with MacAndrews & Forbes Group LLC (“M&F Group”), the
Company’s largest shareholder, pursuant to which M&F Group has committed
to purchase, at the Company’s option and exercisable on demand during a
one-year period after the date of the Letter Agreement, up to 5,454,545
unregistered shares of Common Stock at a fixed price of $1.65 per share
for aggregate proceeds of approximately $9.0 million assuming the
Company elects to sell the entire amount. M&F Group may also exercise a
right to purchase those shares on the same terms three times during the
same one-year period.

“This financing allows us to initiate two important trials to study
therapeutics for underserved populations, one for Type 1 diabetics who
rely primarily on insulin and a second for diabetics with Alzheimer’s,”
said Steve Holcombe, the chief executive officer of vTv Therapeutics.
“We expect readouts from these trials in the first quarter of next year
and fourth quarter of next year, respectively.”

The Company intends to use the net proceeds from the Registered Direct
Offering and the Letter Agreement to fund start-up activities for
current and future clinical trials, in addition to ongoing business
operations. The clinical trials include:

• • A phase 2 and phase 3 clinical trial under a single protocol designed
    to investigate the safety and efficacy of azeliragon in
    patients with mild Alzheimer’s disease and type 2 diabetes as
    evidenced by elevated HbA1c.

• • The part 2 confirmatory phase of the ongoing Simplici-T1 Study, a
    12-week study to evaluate TTP399 as an add-on to insulin therapy for
    type 1 diabetics. This trial is being conducted in partnership with
    JDRF.